During a night shift when she was a resident at Yale New Haven Hospital, Cristiana Baloescu was taking care of a patient with ...

Chronic obstructive pulmonary disease (COPD) is one of the major causes of morbidity and mortality in the United State. The investigation of the continuing increase in its prevalence and mortality has ...

Introduction: Emergency laparotomy (EL) remains one of the highest-risk procedures in general surgery, characterized by substantial postoperative morbidity and mortality. Despite major advances in ...

Please provide your email address to receive an email when new articles are posted on . Smoking abstinence during week 9 to week 12 among adults with COPD was 19.1% with 12-cytisinicline vs. 4.3% with ...

In support of World COPD Day on November 19, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), is drawing attention to the importance of correctly diagnosing COPD earlier - with the ...

AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...

Situated between the Appalachian and Blue Ridge ranges, West Virginia is known as the ‘mountain state’ and many of its counties are considered rural. Caroline lived in one such rural farming community ...

Eating foods high in omega-3s, like salmon and walnuts, may help your lungs work better. Refined carbs and processed meats can harm lung function and should be avoided. Diet, exercise, and avoiding ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

Background Studies on pulmonary embolism (PE) rule-out strategies traditionally recruited patients in the ED. This method is increasingly impractical given excessive pressures experienced in EDs.

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken a hit after the anti-ST2 monoclonal antibody failed to reduce flare-ups in ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly lower disease exacerbation rates versus placebo in patients with chronic ...